Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Pain
- Drugs
- Wound Care
- Disease
- Medical
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 372542
License Grant
Licensor grants
– the exclusive license, even as to Licensor, including the right to grant sublicenses. under the Licensor Patents, the Licensor Know-How. the Licensor Core Technology. the Licensor Core Technology Inventions and the Licensor Trademark, if any, in the Territory, to make, have made, use and Commercialize the Compound, the Product and Product Improvements in the Territory.
License Property
Licensor has discovered a proprietary compound of the TRPV-1 receptor modulator and neuronal calcium channel blocker class known as Civamide and also referred to as Zucapsaicin, including. without limitation, the Product, and potential back-up compounds and possesses proprietary technology and intellectual property rights.
Compound means the form of cis-8-methvl-N-vanillyl-6-nonenamide, referred to as Civamide and/or also as Zucapsaicin Covered by any of the Licensor Patents and/or, eligible to Data Protection.
The patent is titled Method for treating painful, inflammatory or allergic disorders (civamide).
Invention means a Product-Related Invention or a Licensor Core Technology Invention.
Product means the human pharmaceutical products containing the Compound as an active pharmaceutical ingredient in a topical form for the treatment of Osteo-Arthritis, Covered or not Covered, by any of the Licensor Patents, excluding the Microencapsulated Cream defined herein.
Trademark means Licensors proprietary trademark CIVANEXTM.
Field of Use
The licensing agreement is for CIVANEX® Cream (civamide 0.075%) for the treatment of signs and symptoms of osteoarthritis. Zucapsaicin (Civanex) is a medication used to treat osteoarthritis of the knee and other neuropathic pain. It is applied three times daily for a maximum of three months. Zucapsaicin is a member of phenols and a member of methoxybenzenes[1] It is a modulator of transient receptor potential cation channel subfamily V member 1 (TRPV-1), also known as the vanilloid or capsaicin receptor 1 that reduces pain, and improves articular functions.
IPSCIO Record ID: 174320
License Grant
Pursuant to a merger agreement the Licensor and a third party grant to Licensee an exclusive license during the term of this Agreement under the Patents and Know-how to Sell the Licensed Products and improvements in the Territory. Licensee shall have the right to sublicense all or part of its rights under this Agreement.
License Property
Licensor is the owner of all right, title and interest in an invention relating to cis-capsaicin, also known as civamide, for, among other things, topical products for application to the skin and has developed a treatment for certain conditions in which the application of this invention provides beneficial results. The patents are U.S. 5,063,060 and Canadian 207 0 685. The patent addresses pain, inflammation and allergies.
Field of Use
'Licensed Products' shall mean the topical pharmaceutical products for application to the skin (but not limited to dermatological products) containing cis-capsaicin (also known as civamide) as claimed in the Patents.
IPSCIO Record ID: 390159
License Grant
Licensor granted Virgin Island Licensee exclusive global rights to develop, manufacture and commercialize a portfolio of novel, small-molecule CGRP receptor antagonists for the treatment of CGRP-mediated disorders, including non-migraine indications. This includes in-licensed patents and patent applications in the U.S. and foreign countries directed to CGRP receptor antagonists.
License Property
The portfolio included the lead candidate HTL0022562, referred to as BHV-3100, which had advanced through preclinical development demonstrating promising and differentiated properties for further investigation in human trials. BHV-3100, the most advanced candidate in a portfolio of novel, small-molecule CGRP receptor antagonists being developed. BHV-3100, previously known as HTL0022562, was developed successfully through preclinical trials by Licensor and demonstrated promising and differentiated properties in target CGRP-mediated disorders.
The patents and patent applications disclose novel compounds, pharmaceutical compositions and methods of treating various diseases including those other than migraine such as pain, hot flashes, cluster headache and other CGRP-mediated cerebrovascular and vascular disorders. The patents and patent applications include, for example, U.S. Patents 9,808,457 and 10,300,056.
U.S. Patent 9,808,457 – CGRP receptor antagonists
U.S. Patent 10,300,056 – CGRP receptor antagonists
Calcitonin gene related peptide (CGRP) receptor antagonism, glutamate modulation, myeloperoxidase ('MPO') inhibition, Kv7 Ion Channel Activators (Kv7), and Myostatin.
Field of Use
The rights granted is for for the treatment of CGRP-mediated disorders, including non-migraine indications.
CGRP stands for calcitonin gene-related peptide, and it is a protein that is released around the brain. When CGRP is released, it causes intense inflammation in the coverings of the brain (the meninges), and for most migraine patients, causes the pain of a migraine attack.
Licensee is a biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders.
IPSCIO Record ID: 319352
License Grant
Licensor (of the United Kindgom) granted Licensee the exclusive global rights to discover, develop, make, sell, market, and otherwise commercialize any pharmaceutical composition or preparation (in any and all dosage forms) in final form containing one or more compounds, including Epoladerm and OSF200, that was developed, manufactured or commercialized utilizing Licensor’s spray formulation technology (Licensor Product), to be used for any and all uses in humans (including all diagnostic, therapeutic and preventative uses).
License Property
Topical Spray Technology product mean DSF100 or EpoladermTM and OSF200, a topical nonsteroidal anti-inflammatory drug. This Technology is a therapeutic treatment for topicals and transdermal deliveries due to its adhesion and accessibility properties, especially around joints and curved body surfaces.
OSF200 – for chronic osteoarthritis of the knee
DSF100 or EpoladermTM – for acute musculoskeletal pain
The product candidate is covered by US Patent No. 8,349,297. The patents contain broad composition claims to a platform of pharmaceutical formulations which form a film on spray administration where the active agent is present at least 80% saturation and there is no undissolved active agent in the formulation. The claims also include a method of treatment and an aerosol dispenser containing the formulation.
8,349,297 – Topical formulations
Field of Use
The field of use is for the treatment of pain to be used for any and all uses in humans (including all diagnostic, therapeutic and preventative uses) and not limited to, treatment of estrogen levels, Alzheimer’s disease, dementia, Parkinson’s disease, neuropathic issues, and acute and chronic pain such as acute musculoskeletal pain and chronic osteoarthritis of the knee.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
